Skip to main content
Use of Medtronic's CoreValve TAVR systems expanded by FDA

Medtronic has obtained an expanded indication from the FDA for its CoreValve transcatheter aortic-valve replacement systems for use in treating severe aortic stenosis patients who are at an intermediate risk for surgery. The decision was backed by results from a 1,746-patient trial showing that, at two years, TAVR led to a lower rate of disabling stroke or all-cause mortality than surgical valve replacement.

Full Story: